What is the Market's View on Sorrento Therapeutics Inc (SRNE) Stock's Price and Volume Trends Wednesday?

Overall market sentiment has been high on Sorrento Therapeutics Inc (SRNE) stock lately. SRNE receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Sorrento Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on SRNE!

See Full SRNE Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With SRNE Stock Today?

Sorrento Therapeutics Inc (SRNE) stock is higher by 1.27% while the S&P 500 is lower by -2.27% as of 11:21 AM on Wednesday, May 18. SRNE has gained $0.02 from the previous closing price of $1.57 on volume of 2,427,161 shares. Over the past year the S&P 500 is down -4.01% while SRNE is lower by -76.09%. SRNE lost -$1.55 per share in the over the last 12 months.

More About Sorrento Therapeutics Inc

Sorrento Therapeutics Inc is a biotechnology company focused on the development of novel immunotherapies for oncology and autoimmune/inflammation diseases. The antibody technologies target various locations: extracellular, intracellular, and membrane-bound antigens. The product portfolio consists of BioSimilar/BioBetter antibodies, CAR-T programs for the treatment of solid tumors, adoptive cellular therapies, immuno-oncology mAbs, and antibody-drug conjugates. Click Here to get the full Stock Report for Sorrento Therapeutics Inc stock.